Resmed
ResMed Inc., a leading player in the sleep and respiratory care industry, is headquartered in the United States, with significant operations across Europe, Asia, and Australia. Founded in 1989, ResMed has consistently innovated in the development of cloud-connected devices and software solutions that enhance patient care and improve quality of life for those with sleep apnoea and chronic obstructive pulmonary disease (COPD). The company’s core offerings include advanced continuous positive airway pressure (CPAP) devices, portable oxygen concentrators, and digital health solutions, all designed to provide seamless integration and user-friendly experiences. ResMed's commitment to research and development has positioned it as a market leader, recognised for its pioneering technologies and significant contributions to the field of sleep medicine. With a strong focus on improving patient outcomes, ResMed continues to set benchmarks in the healthcare industry.
DitchCarbon Score
How does Resmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Resmed's score of 60 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Resmed's reported carbon emissions
In 2023, ResMed reported total carbon emissions of approximately 28,391,000 kg CO2e, with Scope 1 emissions at about 4,453,000 kg CO2e and Scope 2 emissions at approximately 23,939,000 kg CO2e. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2050, using FY2022 as the base year. For near-term targets, ResMed has committed to reducing absolute Scope 1 and 2 emissions by 42% by FY2030. Additionally, the company plans to decrease Scope 3 emissions by 51.6% per megawatt (MW) constructed within the same timeframe. Long-term goals include a 90% reduction in Scope 1 and 2 emissions and a 97% reduction in Scope 3 emissions per MW constructed by 2050. ResMed's emissions data reflects a proactive approach to sustainability, aligning with industry standards and the Science Based Targets initiative (SBTi) to ensure their targets are consistent with limiting global warming to 1.5°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Resmed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
